)
Covalon Technologies (COV) investor relations material
Covalon Technologies Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue reached $10,041,033 (CAD 10 million), up 20% year-over-year, with growth across all sales channels, led by U.S. vascular access and contamination protection solutions.
Gross profit rose 73% to $6,745,607 (CAD 6.7 million), with gross margin improving to 67.2% from 46.5% last year, driven by high-margin U.S. vascular business and favorable inventory adjustments.
Net income for Q3 was $2,810,837 (CAD 2.8 million), a significant increase from the prior year; adjusted EBITDA was $3.0 million, more than triple last year.
Cash position increased to $19.4 million at quarter-end, up $2.8 million from the previous quarter, with no bank debt.
All key financial metrics—revenue, gross profit, gross margin, adjusted gross margin, and adjusted EBITDA—were the highest in any quarter in the past five years.
Financial highlights
Q3 gross margin was 67.2%, up from 46.5% last year; adjusted gross margin was 66.4% versus 55.6%.
Operating expenses remained stable at $4,018,397 (CAD 4 million), up just 1% year-over-year.
Generated $7.4 million in operating cash flow in nine months, up from $3.0 million last year.
Paid out $4.1 million in the first-ever dividend and invested over $1 million in capital expenditures.
Year-to-date revenue was $25,656,349 (CAD 26 million), up 6% year-over-year, with net income more than doubling to $4 million and EPS rising to $0.15.
Outlook and guidance
Management expressed strong optimism for continued growth, citing robust sales momentum, expanding adoption of key products, and a robust pipeline for hospital opportunities.
Investments in manufacturing and regulatory submissions are expected to support future efficiency and international expansion.
Fiscal 2026 is on track for strong performance, with growth expected to continue into next year and beyond.
Focus remains on expanding contamination protection solutions and driving value creation.
Management highlights massive further opportunity with existing account penetration and new account acquisition.
- Q2 revenue up 14.9% with margin expansion and rapid clinical product adoption.COV
Q2 2026 - Q2 sales and orders already exceed Q1, supporting a strong outlook and industry momentum.COV
Q1 2026 - Record Q4 revenue, $0.15 dividend, $17M cash, and strong growth in key channels.COV
Q4 2025 - Strong U.S. growth, clinical impact, and a special dividend highlight strategic momentum.COV
Planet MicroCap Showcase: TORONTO 2025 - Sequential revenue and EBITDA growth, strong cash, and new clinical evidence drive outlook.COV
Q3 2025 - Strong U.S. growth, profitability turnaround, and innovation position the company for expansion.COV
Planet MicroCap Showcase: VANCOUVER 2024 - Q3 revenue up 47% to $9.2M, with adjusted EBITDA of $2.4M and EPS of $0.06.COV
Q3 2024 - 75% revenue growth and strong US consumables sales drove profitability and industry recognition.COV
Q1 2025 - Double-digit revenue growth, positive net income, and strong cash position in FY2024.COV
Q4 2024
Next Covalon Technologies earnings date
Next Covalon Technologies earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)